|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvedBy
|
2006 (US)
|
|
gptkbp:ATCCode
|
C01EB18
|
|
gptkbp:bioavailability
|
35-50%
|
|
gptkbp:brand
|
gptkb:Ranexa
|
|
gptkbp:CASNumber
|
95635-55-5
|
|
gptkbp:chemicalClass
|
piperazine derivative
|
|
gptkbp:contraindication
|
liver cirrhosis
QT prolongation
strong CYP3A inhibitors
|
|
gptkbp:developedBy
|
gptkb:CV_Therapeutics
|
|
gptkbp:eliminationHalfLife
|
7 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:FDA_label
|
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021526s020lbl.pdf
|
|
gptkbp:hasMolecularFormula
|
C24H33N3O4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ranolazine
|
|
gptkbp:IUPACName
|
N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
|
|
gptkbp:KEGGID
|
D08325
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Gilead_Sciences
|
|
gptkbp:mechanismOfAction
|
inhibits late phase of the inward sodium current
|
|
gptkbp:MedlinePlusID
|
a606020
|
|
gptkbp:metabolism
|
liver (CYP3A, CYP2D6)
|
|
gptkbp:molecularWeight
|
427.54 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
62%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
104741
DB00243
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
constipation
dizziness
headache
|
|
gptkbp:UNII
|
57U869V4RU
|
|
gptkbp:usedFor
|
chronic angina
|
|
gptkbp:bfsParent
|
gptkb:CV_Therapeutics
|
|
gptkbp:bfsLayer
|
6
|